- Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis2016 | 1. lékařská fakulta
- BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis2011 | 1. lékařská fakulta
- BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis2011 | 2. lékařská fakulta
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study2012 | 1. lékařská fakulta
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study2012 | 2. lékařská fakulta
- MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS2007 | 1. lékařská fakulta
- Nasolabial Flaps in the Treatment of MRONJ2019 | 1. lékařská fakulta
- MR monitorace aktivity pacientů s roztroušenou sklerózou (konvenční techniky, výsledky dlouhodobé MR monitorace léčby ocrelizumabem)2019 | 1. lékařská fakulta
- Early magnetic resonance imaging predictors of clinical progression after 48months in clinically isolated syndrome patients treated with intramuscular interferon beta-1a2015 | 1. lékařská fakulta
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS2016 | 1. lékařská fakulta
- Solitary tuberculous brain lesions: 24 new cases and a review of the literature2014 | 1. lékařská fakulta
- Alemtuzumab2014 | 1. lékařská fakulta
- Clinical Experience with Autofluorescence Guided Oral Squamous Cell Carcinoma Surgery2023 | Lékařská fakulta v Plzni
- No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a2018 | 1. lékařská fakulta
- Hematopoietic stem cell transplantation for multiple sclerosis2005 | 3. lékařská fakulta
- Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?2017 | 1. lékařská fakulta
- Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study2014 | 1. lékařská fakulta
- Meningiomatosis in an AIDS Patient Receiving Highly Active Antiretroviral Therapy (HAART)2016 | 1. lékařská fakulta
- Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management2018 | 1. lékařská fakulta
- Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study2014 | 1. lékařská fakulta
- Central nervous system lymphoma: a morphological MRI study2016 | 2. lékařská fakulta, Ústřední knihovna
- Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study2019 | 1. lékařská fakulta
- Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial2022 | 1. lékařská fakulta
- Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study2013 | 1. lékařská fakulta
- Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event2013 | 1. lékařská fakulta
- Comparative efficacy of first-line natalizumab vs IFN-Beta or glatiramer acetate in relapsing MS2016 | 1. lékařská fakulta
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study2017 | 1. lékařská fakulta
- Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis2020 | 1. lékařská fakulta
- Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies2017 | 1. lékařská fakulta
- Monitoring of radiologic disease activity by serum neurofilaments in MS2020 | 1. lékařská fakulta